Brooks Laboratories Gains 1.55%: 2 Key Circuit Hits Define Volatile Week

1 June 2026: Upper Circuit Triggered by Strong Buying Momentum

Brooks Laboratories Ltd surged to hit its upper circuit limit on 1 June 2026, closing at Rs.68.55, a gain of 4.87% from the previous close. This move was driven by robust investor demand and sustained buying pressure, with the stock opening sharply higher and maintaining upward momentum throughout the session. The stock’s intraday range was relatively narrow, with a low of Rs.67.50 and a high at the circuit limit of Rs.68.55.

Trading volumes were notably high for a micro-cap stock, with approximately 1.12 lakh shares changing hands and a turnover of Rs.0.77 crore. Delivery volumes had surged by 288.28% compared to the five-day average on 29 May, signalling genuine investor commitment rather than speculative trading. Despite the regulatory freeze on further buying after hitting the circuit, the stock’s performance stood out, outperforming its Pharmaceuticals & Biotechnology sector which declined by 0.44% and the Sensex which fell 0.96% that day.

Technically, the stock was trading above its short- and medium-term moving averages (5-day, 20-day, 50-day, 100-day), indicating positive momentum, though it remained below the 200-day average, suggesting longer-term resistance. The upper circuit hit capped a nine-day winning streak that had delivered a cumulative return of 48.63%, underscoring strong investor optimism.

2 June 2026: Sharp Reversal as Stock Hits Lower Circuit Amid Heavy Selling

The optimism of the previous day was sharply reversed on 2 June 2026, when Brooks Laboratories Ltd plunged to its lower circuit limit, closing at Rs.65.86, down 4.99%. The stock exhibited extreme volatility, opening with an intraday high of Rs.71.90 (up 4.89%) before succumbing to intense selling pressure that drove it down to Rs.65.13, the circuit low.

Trading volumes remained substantial at over 1.06 lakh shares, with a turnover of Rs.0.72 crore. Delivery volumes increased by 26.43% compared to the five-day average on 1 June, indicating active participation but predominantly on the sell side. This selling pressure overwhelmed buying interest, ending the stock’s nine-day winning streak and signalling a potential trend reversal.

Relative to the broader market, the stock underperformed its sector, which declined by 0.77%, and the Sensex, which gained 0.43%. Technically, while the stock remained above its short- and medium-term moving averages, it continued to trade below the 200-day average, reflecting longer-term bearish pressure. The lower circuit hit highlighted panic selling and heightened risk, particularly given the stock’s micro-cap status and susceptibility to volatility.

Brooks Laboratories’ Mojo Score remained at 31.0 with a Sell grade, downgraded from Strong Sell earlier in February 2026, reflecting cautious analyst sentiment amid deteriorated fundamentals and technical outlook.

3 to 5 June 2026: Stabilisation and Recovery Towards Week Close

Following the sharp decline on 2 June, Brooks Laboratories Ltd continued to experience subdued trading on 3 and 4 June, with prices easing further to Rs.64.50 (-3.37%) and Rs.63.98 (-0.81%) respectively. Volumes were relatively low during these sessions, reflecting cautious investor sentiment amid lingering uncertainty.

On 5 June, the stock rebounded strongly, gaining 4.36% to close at Rs.66.77. This recovery helped the stock finish the week with a net gain of 1.55% from the previous Friday’s close of Rs.65.75, outperforming the Sensex which declined 0.78% over the same period. The rebound suggests some restoration of confidence after the volatile start to the week, though volumes remained moderate at 6,658 shares.

Key Takeaways from the Week

The week for Brooks Laboratories Ltd was characterised by pronounced volatility, with the stock swinging between upper and lower circuit limits on consecutive days. The initial surge on 1 June reflected strong buying interest and positive momentum, supported by increased delivery volumes and outperformance relative to sector and market benchmarks.

However, the sharp reversal on 2 June highlighted the fragility of this rally, as panic selling and heavy supply overwhelmed demand, ending a nine-day winning streak. The stock’s micro-cap status and trading below the 200-day moving average contributed to heightened volatility and risk.

The subsequent stabilisation and recovery towards the week’s close suggest some restoration of investor confidence, though volumes remained moderate. The Mojo Score of 31.0 with a Sell grade indicates that caution remains warranted given the company’s fundamentals and technical outlook.

Investors should note the stock’s tendency for sharp intraday swings and regulatory trading halts, which can impact liquidity and price discovery. The week’s events underscore the importance of monitoring volume patterns, technical indicators, and sector trends when analysing Brooks Laboratories Ltd.

In summary, while Brooks Laboratories Ltd managed a modest weekly gain of 1.55%, the underlying price action was volatile and mixed, reflecting a market grappling with conflicting signals. The stock’s outperformance relative to the Sensex (-0.78%) is notable, but the risks associated with micro-cap volatility and circuit limits remain significant factors for consideration.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →